From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.
News|Articles|April 1, 2025
Dermatology Month in Review: March 2025
Author(s)Tim Smith
Fact checked by: Abigail Brooks, MA
In this review of March 2025 in dermatology news, we highlight a variety of notable stories covered in the field regarding pipeline news and recent data.
Advertisement
Advertisement
In the latest iteration of the Month in Review series, the HCPLive editorial team highlights a variety of notable stories in
Related to this article
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Advertisement
Advertisement